The WHO-HAEM5 specifies that DH lymphomas require MYC and BCL2 rearrangements, called DLBCL or HGBCL with MYC and BCL2 rearrangements because those with BCL6 rearrangement have a diverse gene expression signature. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.